Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Dec 4;5(4):E33.
doi: 10.1208/ps050433.

A photo-crosslinked poly(vinyl alcohol) hydrogel growth factor release vehicle for wound healing applications

Affiliations

A photo-crosslinked poly(vinyl alcohol) hydrogel growth factor release vehicle for wound healing applications

Sharon L Bourke et al. AAPS PharmSci. .

Abstract

The objective of this study was to develop and evaluate a hydrogel vehicle for sustained release of growth factors for wound healing applications. Hydrogels were fabricated using ultraviolet photo-crosslinking of acrylamide-functionalized nondegradable poly(vinyl alcohol) (PVA). Protein permeability was initially assessed using trypsin inhibitor (TI), a 21 000 MW model protein drug. TI permeability was altered by changing the solids content of the gel and by adding hydrophilic PVA fillers. As the PVA content increased from 10% to 20%, protein flux decreased, with no TI permeating through 20% PVA hydrogels. Further increase in model drug release was achieved by incorporating hydrophilic PVA fillers into the hydrogel. As filler molecular weight increased, TI flux increased. The mechanism for this is most likely an alteration in protein/gel interactions and transient variations in water content. The percent protein released was also altered by varying protein loading concentration. Release studies conducted using growth factor in vehicles with hydrophilic filler showed sustained release of platelet-derived growth factor (PDGF-beta,beta) for up to 3 days compared with less than 24 hours in the controls. In vitro bioactivity was demonstrated by doubling of normal human dermal fibroblast numbers when exposed to growth factor-loaded vehicle compared to control. The release vehicle developed in this study uses a rapid and simple fabrication method, and protein release can be tailored by modifying solid content, incorporating biocompatible hydrophilic fillers, and varying protein loading concentration.

PubMed Disclaimer

References

    1. Steed DL. Clinical evaluation of recombinant human plateletderived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21(1):71–78. - PubMed
    1. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled doubleblind study. Diabetes Care. 1998;21(5):822–827. doi: 10.2337/diacare.21.5.822. - DOI - PubMed
    1. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen. 2000;8(6):480–493. doi: 10.1046/j.1524-475x.2000.00480.x. - DOI - PubMed
    1. Arm DM, Tencer AF, Bain SD, Celino D. Effect of controlled release of platelet-derived growth factor from a porous hydroxyapatite implant on bone ingrowth. Biomaterials. 1996;17:703–709. doi: 10.1016/0142-9612(96)86740-8. - DOI - PubMed
    1. Kim HD, Valentini RF. Human osteoblast response in vitro to platelet-derived growth factor and transforming growth factor-β delivered from controlled-release polymer rods. Biomaterials. 1997;18(17):1175–1184. doi: 10.1016/S0142-9612(97)00049-5. - DOI - PubMed

Publication types

LinkOut - more resources